Concentration and Subclass Distribution of Anti-ADAMTS13 IgG Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic Thrombocytopenic Purpura

Background The acquired form of idiopathic thrombotic thrombocytopenic purpura (TTP) is an autoimmune disease, in which the underlying deficiency of the ADAMTS13 protease is caused by autoantibodies, predominantly of the IgG isotype. Certain HLA-DR-DQ haplotypes were associated with the risk of developing TTP. Objectives To investigate the development of the ADAMTS13-specific antibody response during the course of the disease, we analyzed the concentration, subclass distribution, and inhibitory potential of anti-ADAMTS13 IgG autoantibodies in samples of TTP patients drawn during the first acute phase, in remission, and during relapse. Additionally, we compared the anti-ADAMTS13 IgG levels between patients carrying and not carrying risk and protective HLA-DR-DQ haplotypes. Patients and Methods We determined the anti-ADAMTS13 IgG concentration and subclass distribution in 101 antibody-positive samples of 81 acquired TTP patients by ELISA methods. The presence and semi-quantitative amount of anti-ADAMTS13 inhibitors were determined in 97 of 100 deficient samples, and the specific inhibitory potential of anti-ADAMTS13 autoantibodies was determined in 49 selected samples, by mixing ADAMTS13-activity assays. HLA-DR-DQ typing and haplotype prediction were performed in 70 of the above patients. Results We found that IgG1 and IgG4 were the predominant subclasses, present in almost all samples. While IgG1 was the dominant subclass in almost half of the samples taken during the first acute episode, IgG4 was dominant in all samples taken during or following a relapse. The inhibitory potential of the samples correlated with levels of the IgG4 subclass. Anti-ADAMTS13 antibodies of IgG4-dominant samples had higher specific inhibitory potentials than IgG1-dominant samples, independently of disease stage. Interestingly, we found that patients carrying the protective DR7-DQ2 and DR13-DQ6 haplotypes had higher anti-ADAMTS13 IgG levels. Conclusion Our results indicate that IgG4 becomes the dominant subtype at some point of the disease course, apparently before the first relapse, parallel to the increase in inhibitory potential of the anti-ADAMTS13 autoantibodies. Furthermore, we found an association between the genetic background and the antibody response in TTP.

[1]  M. Schaller,et al.  Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome , 2018, Journal of thrombosis and haemostasis : JTH.

[2]  I. Koneczny A New Classification System for IgG4 Autoantibodies , 2018, Front. Immunol..

[3]  A. Verkman,et al.  Mechanisms of Autoantibody-Induced Pathology , 2017, Front. Immunol..

[4]  S. Vesely,et al.  Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. , 2017, Blood advances.

[5]  A. Tordai,et al.  The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura. , 2017, Human immunology.

[6]  E. Ostertag,et al.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro , 2016, Transfusion.

[7]  A. ten Brinke,et al.  CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides. , 2016, Blood.

[8]  M. Scully,et al.  Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura☆ , 2015, EBioMedicine.

[9]  B. Lämmle,et al.  The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. , 2014, Blood.

[10]  S. Ferrari,et al.  Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura , 2014, Haematologica.

[11]  A. ten Brinke,et al.  Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. , 2012, Blood.

[12]  D. Consonni,et al.  ADAMTS‐13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura , 2012, Journal of thrombosis and haemostasis : JTH.

[13]  I. Scharrer,et al.  The role of human leukocyte antigens as predisposing and/or protective factors in patients with idiopathic thrombotic thrombocytopenic purpura , 2012, Annals of Hematology.

[14]  J. Voorberg,et al.  Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain , 2011, Haematologica.

[15]  Eric Rondeau,et al.  Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience , 2010, PloS one.

[16]  É. Azoulay,et al.  HLA‐DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency‐related idiopathic thrombotic thrombocytopenic purpura in Caucasians , 2010, Journal of thrombosis and haemostasis : JTH.

[17]  S. Vesely,et al.  Survival and relapse in patients with thrombotic thrombocytopenic purpura. , 2010, Blood.

[18]  M. Scully,et al.  Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link , 2010, Journal of thrombosis and haemostasis : JTH.

[19]  J. Mira,et al.  HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians. , 2009 .

[20]  S. Ferrari,et al.  IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura , 2009, Journal of thrombosis and haemostasis : JTH.

[21]  Z. Prohászka,et al.  Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure , 2009, Thrombosis and Haemostasis.

[22]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[23]  J. Voorberg,et al.  VH1‐69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura , 2009, Journal of thrombosis and haemostasis : JTH.

[24]  F. Fabris,et al.  ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission , 2008, Haematologica.

[25]  P. Parren,et al.  Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.

[26]  É. Oksenhendler,et al.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.

[27]  J. V. van Mourik,et al.  Multiple B‐cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type‐1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura , 2006, Journal of thrombosis and haemostasis : JTH.

[28]  X. Zheng,et al.  Inhibitory autoantibodies against ADAMTS‐13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS‐13 protease and may accelerate its clearance in vivo , 2006, Journal of thrombosis and haemostasis : JTH.

[29]  H. Deckmyn,et al.  ADAMTS‐13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences , 2006, Journal of thrombosis and haemostasis : JTH.

[30]  B. Lämmle,et al.  ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. , 2005, Blood.

[31]  M. Stephens,et al.  Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-data Imputation , 2022 .

[32]  F. Dorner,et al.  Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. , 2003, Blood.

[33]  G. Hutchins,et al.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. , 2003, Archives of pathology & laboratory medicine.

[34]  K. Fujikawa,et al.  Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura* , 2001, The Journal of Biological Chemistry.

[35]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[36]  K. Fujikawa,et al.  Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. , 2001, Blood.

[37]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[38]  B. Lämmle,et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1998, The New England journal of medicine.

[39]  H. Tsai,et al.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. , 1998, The New England journal of medicine.

[40]  B. Lämmle,et al.  Deficient Activity of von Willebrand Factor–Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura , 1997 .

[41]  M. Neuberger,et al.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.

[42]  R. Aalberse,et al.  Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. , 1986, Journal of immunology.

[43]  R. Aalberse,et al.  Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. , 1983, Journal of immunology.

[44]  D. Deykin,et al.  Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. , 1982, The New England journal of medicine.

[45]  K. N. Dollman,et al.  - 1 , 1743 .